Moomoo AI 已提取核心訊息
Vivos Therapeutics, Inc., a company specializing in medical devices and procedures for treating sleep-disordered breathing, has filed an amended Schedule 13G/A with the SEC, indicating changes in ownership by significant shareholders. The filing, dated December 31, 2023, and submitted on February 14, 2024, reveals that Coronado V Partners, LLC and R. Kirk Huntsman, the President of Coronado V Partners, LLC, collectively hold a significant portion of the company's shares. Coronado V Partners, LLC owns 69,600 shares, representing 3.2% of the company's common stock, while R. Kirk Huntsman individually holds 94,794 shares, accounting for 4.3% of the common stock. The total shares outstanding of Vivos Therapeutics' common stock are 2,207,651 as of February 13, 2024. The filing also notes that the reported share amounts and percentages reflect the effects of a 1-for-25 reverse stock split that took effect on October 25, 2023. Additionally, the filing indicates that R. Kirk Huntsman has ceased to be the beneficial owner of more than five percent of the class of securities.
Vivos Therapeutics, Inc., a company specializing in medical devices and procedures for treating sleep-disordered breathing, has filed an amended Schedule 13G/A with the SEC, indicating changes in ownership by significant shareholders. The filing, dated December 31, 2023, and submitted on February 14, 2024, reveals that Coronado V Partners, LLC and R. Kirk Huntsman, the President of Coronado V Partners, LLC, collectively hold a significant portion of the company's shares. Coronado V Partners, LLC owns 69,600 shares, representing 3.2% of the company's common stock, while R. Kirk Huntsman individually holds 94,794 shares, accounting for 4.3% of the common stock. The total shares outstanding of Vivos Therapeutics' common stock are 2,207,651 as of February 13, 2024. The filing also notes that the reported share amounts and percentages reflect the effects of a 1-for-25 reverse stock split that took effect on October 25, 2023. Additionally, the filing indicates that R. Kirk Huntsman has ceased to be the beneficial owner of more than five percent of the class of securities.
專門從事治療睡眠呼吸障礙的醫療器械和手術的公司Vivos Therapeutics, Inc. 已向美國證券交易委員會提交了經修訂的附表13G/A，表明大股東的所有權發生了變化。這份日期爲2023年12月31日並於2024年2月14日提交的文件顯示，Coronado V Partners, LLC和Coronado V Partners, LLC總裁R. Kirk Huntsman共同持有該公司的很大一部分股份。Coronado V Partners, LLC擁有69,600股股票，佔公司普通股的3.2％，而R. Kirk Huntsman個人持有94,794股股票，佔普通股的4.3％。截至2...展開全部
專門從事治療睡眠呼吸障礙的醫療器械和手術的公司Vivos Therapeutics, Inc. 已向美國證券交易委員會提交了經修訂的附表13G/A，表明大股東的所有權發生了變化。這份日期爲2023年12月31日並於2024年2月14日提交的文件顯示，Coronado V Partners, LLC和Coronado V Partners, LLC總裁R. Kirk Huntsman共同持有該公司的很大一部分股份。Coronado V Partners, LLC擁有69,600股股票，佔公司普通股的3.2％，而R. Kirk Huntsman個人持有94,794股股票，佔普通股的4.3％。截至2024年2月13日，Vivos Therapeutics普通股的已發行總股數爲2,207,651股。該文件還指出，報告的股票金額和百分比反映了2023年10月25日生效的1比25反向股票拆分的影響。此外，該文件顯示，R. Kirk Huntsman已不再是該類別超過5％的證券的受益所有人。
有用
沒用